Objectives: Therapeutic hypothermia (TH) is now standard treatment for moderate to severe hypoxic ischemic encephalopathy (HIE), secondary to intrapartum hypoxia, and has been performed in our neonatal unit since 2008. Objectives of this study included the assessment of compliance with the TH protocol and the evaluation of 2-year outcomes. Materials and Methods: Medical records of all the infants who underwent TH (2008)(2009)(2010)(2011)(2012)(2013)(2014) were reviewed and relevant data were extracted. The laboratory database was used to extract blood test results. Follow-up clinic records were reviewed to gather data for 2-year outcomes. Outcome at 2 years was dichotomized as normal (survival with no or mild impairment) and abnormal (death or survival with moderate or severe impairment). Regression analysis was performed to determine the association of perinatal variables with an abnormal outcome. Results: Seventy-seven infants were treated with TH with 40/77 (52%) cooled as per the protocol. Treatment with TH for stage 1 HIE was the most common reason for protocol noncompliance. A total of 71 infants had HIE (n = 26, 24, and 21 with modified Sarnat stages 1, 2, and 3 respectively). Sixteen infants with HIE (22.5%) died; all had stage 3 HIE. Forty-one infants were seen at ≥2 years. Of these, 34 infants (83%) had a normal outcome. The clinical stage of HIE was the strongest predictor of an abnormal outcome. Normal 2-year outcome was seen in 94%, 84%, and 5% of stages 1, 2, and 3 HIE respectively. Conclusions: We noted a high degree of variation from the TH protocol. Clinical staging of HIE remains the strongest predictor of long-term outcome.
Introduction
Hypoxic ischemic encephalopathy (HIE) following perinatal asphyxia is the most common cause of neonatal encephalopathy. In recent years, therapeutic hypothermia (TH) has become the standard of care for moderate to severe HIE following the results from large multicenter trials. [1] [2] [3] As experience with TH has accumulated, the neonatal care community has become reassured about its safety, and now the treatment is also offered to infants outside the trial criteria. 4, 5 Since 2008, TH has been offered to infants with perinatal HIE in our unit under a standard protocol. 1 The primary objective for this study was to assess our compliance with this protocol. The secondary objective was to evaluate the 2-year outcome data for infants who received TH and correlate this with the clinical variables.
Materials and Methods
This retrospective study was conducted at the tertiary neonatal unit of Westmead Hospital in Sydney, Australia. Medical records of all the infants who underwent TH from 2008 to 2014 were reviewed and relevant data were extracted. The laboratory database was used to extract the results of the blood tests and electroencephalography (EEG). We also reviewed the records from the follow-up clinic to collect data about 2-year outcome. Table 1 shows the data items collected. 1 Westmead Hospital, Darcy Rd., Westmead NSW 2145, Australia. We calculated cumulative exposure to hypocarbia (hypocarbia time) as the difference between 35 mm Hg and the sampled PaCO 2 multiplied by the duration in minutes spent below 35 mm Hg. 6 The time from birth to the time when the plasma lactate level first fell below 2 mmol/L was calculated in hours (lactate time). Cerebral magnetic resonance imaging (MRI) scans were classified as normal, mildly abnormal (mild to moderate white matter changes), or severely abnormal (changes in the thalamus and/or basal ganglia and/or posterior limb of the internal capsule or severe white matter changes). 
Inclusion criteria
The TH protocol defined the eligibility criteria for whole-body cooling and mandated meeting all the following 4 criteria: a. gestation ≥35 weeks b. postnatal age <6 hours c. evidence of asphyxia as defined by the presence of at least 2 of the following:
• Apgar score <6 at 10 minute or continued need for resuscitation with positive pressure ventilation ± chest compressions at 10 minute All surviving infants were enrolled for the followup program and were reviewed by a neonatologist, physiotherapist, and occupational therapist at 4 and 8 months of age. At 12 and 24 months of age, these infants were assessed using Bayley Scale of Infant and Toddler Development: Third edition (BSID III) 9 and scores were derived for cognitive, language, and motor domains. A composite score of 100 (SD 15) was considered normal. All the infants were also referred for formal audiological evaluation and an ophthalmological evaluation was sought if there were any visual concerns.
Mild impairment was defined as a BSID-III composite score in 1 or more domains that was 1 to 2 SD below the mean and/or the presence of cerebral palsy (CP) with the Gross Motor Function Classification System (GMFCS)
10 Level 1. Moderate impairment was defined as the presence of any one of ambulant CP (GMFCS Level 2), functionally impaired vision, hearing loss improved by hearing aids, or a composite score of 2 to 3 SD below the mean in 1 or more domains using the BSID III. Severe impairment was defined as nonambulant CP (GMFCS Levels 3-5), blindness, profound sensorineural hearing loss not improved by hearing aids, or a composite score > 3SD below the mean in 1 or more domains using the BSID III. Outcomes were dichotomized as normal (survival with no or mild impairment) and abnormal (death or survival with moderate-severe impairment).
To assess our compliance with the TH protocol, we reviewed each case to identify any deviation from the unit protocol. Dichotomized outcome data were correlated with the variables as shown in Table 2 . This was to identify prognostic variables in the neonatal period that could potentially predict the risk of mortality or the composite outcome of death or moderate to severe disability. All the variables were analyzed using a logistic regression model. A continuous variable that did not have the parametric distribution was log-transformed and then included into the model. Odds ratios with 95% confidence intervals (CIs) and P values were calculated. All analyses were performed in SPSS Version 22.0 (IBM SPSS Statistics, IBM Corporation, Armonk, NY). This study was approved by the Western Sydney Local Health District ethics committee. 
Results
Over the study period, a total of 77 infants received TH. Their demographic and intrapartum characteristics are summarized in Table 3 . The most common pregnancy complication noted was diabetes (12/77), followed by hypertension (8/77). The sentinel intrapartum events included antepartum hemorrhage because of placental abruption or vasa previa in 13 cases and cord prolapse in four cases. The eligibility criteria for TH were fulfilled by 40 of 77 cooled infants (52%). Figure 1 summarizes the details of noncompliant cases. Cooling for stage 1 HIE was the most common basis for noncompliance. Of the 6 infants with no HIE, 1 was later diagnosed to have congenital myopathy. The neurological examination in the other 5 infants did not show any evidence of encephalopathy and TH was ceased after 24 hours for 3 of them. Delayed onset of cooling was noted in 2 cases and 1 of them was an infant with postnatal collapse beyond 6 hours of age and the other was an infant with onset of seizures at 12 hours of age. Overall, there were 3 infants with postnatal collapse who received TH with variable outcomes (1 death, 1 with CP, and 1 with normal outcome). TH was generally tolerated well. It was ceased prematurely for 1 infant owning to persistent coagulopathy that was not correctable with blood product replacement.
Of the 71 infants with HIE, 26/71 had stage 1 (36.6%), 24/71 had stage 2 (33.8%), and 21/71 had stage 3 HIE (29.5%). In the neonatal period, 16 infants died, yielding a mortality rate of 35.5% of stages 2 to 3 HIE. All nonsurvivors had stage 3 HIE. Fifteen of the 16 passed away following withdrawal of intensive care measures. Of the 55 survivors, 41 (75%) were seen at 2 years of age, 10 were lost to follow-up, while 4 were followed up at other hospitals. Of the 41 infants who were seen at 2 years of age, 34 (83%) had a normal outcome. Twenty-three survivors of stages 2 to 3 HIE were seen at 2 years and 17 (74%) had a normal outcome. Table 4 shows the outcomes according to the stages of HIE.
Univariate regression analysis showed an abnormal outcome to be significantly associated with lower gestation, Apgar score <4 at 10 minutes, arterial cord gas parameters (low pH, high base deficit, and high lactate level), stage 3 HIE, hyperglycemia, severely abnormal MRI finding, hypocarbia, and lactate time. Stage 3 HIE was the strongest association. Similar analysis showed mortality to be significantly associated with lower gestation and birth weight, Apgar score <4 at 10 minutes, low arterial cord pH and high base deficit, hyperglycemia, severely abnormal MRI finding, hypocarbia, lactate time, and high troponin level on day 1. There were few normal EEGs to analyze any associations. We could not perform multivariate regression because of the small sample size. These findings are shown in Table 5 . Table 6 presents the continuous variables that had significant differences between the 2 groups of outcomes. 
Discussion
In our retrospective study on TH, we noted that almost half of the cooled infants received this treatment outside the eligibility criteria as defined in the unit protocol. Just over one-third of the infants with moderate to severe encephalopathy did not survive. The majority of survivors receiving TH had a good outcome. TH provision to infants with stage 1 HIE was the single largest reason for noncompliance with the unit protocol. Most of the large randomized controlled trials (RCTs) on TH have included infants with moderate or severe encephalopathy only, 2,3,11 although another RCT 1 had enrolled 40 infants with mild encephalopathy in a total of 208 participants. Gardiner et al 12 reported that 20% of their cooled infants had stage 1 HIE. Mehta et al 5 have also reported that of the 207 infants who received TH, 104 (50%) did not meet the eligibility criteria as defined in the policy directive. One of the reasons clinicians might offer TH to stage 1 (mild) HIE is the uncertainty about the disease progression and the need to commence TH within 6 hours of age. In their cohort of 60 infants, Horn et al 13 did not see moderate to severe encephalopathy in 18 infants at 3 to 5 hours of age; however, one-third of this group progressed to this category within 72 hours. The favorable risk-benefit profile of TH may be another factor influencing this decision. In our study, TH was generally safe with early discontinuation because of persistent coagulopathy in 1 infant only. It was likely that the coagulopathy was on account of the underlying disease only. Some of our patients received TH despite there being no evidence of encephalopathy, and this may again relate to the difficulty in neurological assessment. This, however, is concerning. The use of amplitude-integrated EEG (aEEG) may help in such cases to determine the need for TH.
14,15 The mortality rate in our study for stages 2 to 3 HIE (35.5%) was slightly higher than that reported by other authors in their cooled cohorts (17.3%-25.8%) 3, 11, 12 but was similar to the data from the CoolCap study's cooled arm (33.3%). 2 As all the infants with stage 3 HIE died, we can only speculate that the death was related to clinicians'knowledge of the dismal prognosis in this group of infants. The neurodevelopmental impairment among the survivors of stages 2 to 3 HIE (26%) was similar to that reported by other authors (23%-28%) 3, 11, 12 and less frequent compared with the CoolCap study 2 where 32% of the "cooled" survivors had severe disability at 18 months of age. Our figures of mortality and disability in survivors (22.5% and 17% respectively) compared favorably with the results of Jacobs et al 1 (25.2% and 35% respectively) when all stages of HIE were included, although we acknowledge that we had a higher proportion of stage 1 HIE (36.6% as against 15%).
The associations with abnormal outcomes seen on the univariate analysis were not surprising and reflected the degree of illness and brain injury in the infants. Hyperglycemia, hypocarbia, and lactate time were associated with both death and the composite outcome of death and/or moderate to severe impairment. In a newborn piglet model, significant reductions in brain adenosine triphosphate and phosphocreatine were seen when hyperglycemia was produced during the immediatereoxygenation-reperfusion period after inducing hypoxia-ischemia. 16 In human infant studies, 17, 18 hyperglycemia has also been noted as an adverse prognostic factor in HIE. Hypocarbia may contribute to an adverse outcome because of its cerebral vasoconstrictive effects. A recent study supports the relationship between hypocarbia and unfavorable outcome in this group. 19 Lactate is a marker of anaerobic metabolism and a study in adult intensive care patients showed that higher cumulative lactate exposure was associated with in-hospital mortality. 20 The significant association of mortality with troponin concentration seen in our study has been reported previously. 21 The strengths of our study include reporting of contemporary 2-year outcomes in this cohort and focusing attention on protocol deviation. The limitations include its retrospective nature, relatively low 2-year follow-up rate (75%), and small sample size precluding multivariate regression analysis. The unavailability of aEEG data in a standard format is also a limitation.
Future research should include the use of General Movements Assessment from birth in this cohort to assess their predictive value for neurodevelopmental impairment because there is recent literature highlighting their predictive ability in other at-risk infant populations.
22,23

Conclusion
We noted a high degree of off-label use of TH in our unit. Clinical staging of HIE provided the strongest association with abnormal outcomes at 2 years.
